Abatacept therapy has also shown promise myositis; in PM and DM patients treatment resulted in lower disease activity in 8 out of 19 patients [185] and CD4/CD8 T cell ratio in peripheral blood, driven by alterations in CD8+ T cells, correlated positively with muscle endurance improvement [186]. Here, CD8A is linked to dermatomyositis.